Showing results (291-300 of 367) with videos related to

Sort By:
Pageof 37
Leukemia & Lymphoma|August 23, 2006
CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: results of a multi center phase II study and quality of life evaluationYeon Hee Park, Se-Hoon Lee, Won Seog Kim, et al.
Medical Oncology (Northwood, London, England)|April 24, 2008
Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphomaWon Seog Kim, Yeon Hee Park, Se-Hoon Lee, et al.
Biochemical and Biophysical Research Communications|August 1, 2016
The E3 ubiquitin ligase CHIP selectively regulates mutant epidermal growth factor receptor by ubiquitination and degradationChaeuk Chung, Geon Yoo, Tackhoon Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2018
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)Ji-Yeon Kim, Seock-Ah Im, Kyung Hae Jung, et al.
Scientific Reports|June 19, 2023
Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancerKyoungmin Lee, Jongwon Lee, Jungmin Choi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2005
Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter studyJeeyun Lee, Cheolwon Suh, Yeon Hee Park, et al.
JAMA Oncology|July 7, 2022
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical TrialHee Kyung Ahn, Sung Hoon Sim, Koung Jin Suh, et al.
The New England Journal of Medicine|September 16, 2024
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast CancerPeter Schmid, Javier Cortes, Rebecca Dent, et al.
Biochemical and Biophysical Research Communications|July 8, 2017
Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinomaByung Soo Lee, Dong Il Park, Da Hye Lee, et al.
British Journal of Cancer|November 7, 2019
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)Sung Hoon Sim, In Hae Park, Kyung Hae Jung, et al.
Pageof 37